2021 Fiscal Year Final Research Report
New therapeutic strategy for intractable respiratory diseases through CD26/DPP-4
| Project/Area Number |
19K17663
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 53030:Respiratory medicine-related
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | CD26 / 難治性呼吸器疾患 / 肺傷害 / ARDS / Dipeptidyl peptidase 4 |
|---|
| Outline of Final Research Achievements |
In this study, we aimed to clarify roles for CD26/DPP-4 in acute respiratory distress syndrome (ARDS）. Our results indicated that CD26/DPP-4 has pleiotropic effects at cellular levels and is related to the pathological conditions of ARDS.
|
| Free Research Field |
呼吸器疾患
|
| Academic Significance and Societal Importance of the Research Achievements |
CD26/Dipeptidyl peptidase-4(DPP-4)は多面的作用を有するタンパクであり、DPP-4阻害薬は糖尿病薬として臨床で用いられている。本研究によりCD26/DPP-4はARDSにおける治療標的になる可能性が示唆された。したがって、DPP-4阻害薬はARDSの治療薬として新規治療戦略につながる可能性がある。
|
